Christopher Gibson insider trades: Recursion Pharmaceuticals (RXRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
157 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | RXRX | ↓ Sell | 40,000 | $3.08 | $123K | Direct | May 27, 2026 (5d) |
| May 7, 2026 | RXRX | ↓ Sell | 40,000 | $3.37 | $135K | Direct | May 8, 2026 (1d) |
| Apr 7, 2026 | RXRX | ↓ Sell | 40,000 | $3.10 | $124K | Direct | Apr 8, 2026 (1d) |
| Mar 23, 2026 | RXRX | ↓ Sell | 40,000 | $3.25 | $130K | Direct | Mar 25, 2026 (2d) |
| Feb 19, 2026 | RXRX | ↓ Sell | 40,000 | $3.46 | $138K | Direct | Feb 19, 2026 (0d) |
| Feb 4, 2026 | RXRX | ↓ Sell | 40,000 | $4.12 | $165K | Direct | Feb 6, 2026 (2d) |
| Jan 20, 2026 | RXRX | ↓ Sell | 40,000 | $4.47 | $179K | Direct | Jan 22, 2026 (2d) |
| Jan 5, 2026 | RXRX | ↓ Sell | 40,000 | $4.25 | $170K | Direct | Jan 7, 2026 (2d) |
| Dec 19, 2025 | RXRX | ↓ Sell | 40,000 | $4.50 | $180K | Direct | Dec 19, 2025 (0d) |
| Dec 4, 2025 | RXRX | ↓ Sell | 40,000 | $4.63 | $185K | Direct | Dec 5, 2025 (1d) |
| Nov 19, 2025 | RXRX | ↓ Sell | 40,000 | $4.16 | $166K | Direct | Nov 19, 2025 (0d) |
| Nov 4, 2025 | RXRX | ↓ Sell | 40,000 | $5.21 | $208K | Direct | Nov 6, 2025 (2d) |
| Oct 23, 2025 | RXRX | ↓ Sell | 100,000 | $5.70 | $570K | Direct | Oct 24, 2025 (1d) |
| Oct 10, 2025 | RXRX | ↓ Sell | 100,000 | $6.04 | $604K | Direct | Oct 10, 2025 (0d) |
| Sep 25, 2025 | RXRX | ↓ Sell | 100,000 | $4.76 | $476K | Direct | Sep 26, 2025 (1d) |
| Sep 10, 2025 | RXRX | ↓ Sell | 100,000 | $4.71 | $471K | Direct | Sep 12, 2025 (2d) |
| Aug 26, 2025 | RXRX | ↓ Sell | 100,000 | $4.84 | $484K | Direct | Aug 28, 2025 (2d) |
| Aug 11, 2025 | RXRX | ↓ Sell | 500,300 | $5.28 | $2.6M | Direct | Aug 13, 2025 (2d) |
| Aug 11, 2025 | RXRX | ↓ Sell | 100,000 | $5.28 | $528K | by LAHWRAN-3 LLC | Aug 13, 2025 (2d) |
| Aug 11, 2025 | RXRX | ↓ Sell | 17,875 | $5.28 | $94K | by Gibson Family Trust | Aug 13, 2025 (2d) |
| Mar 27, 2025 | RXRX | ↓ Sell | 138,574 | $6.04 | $837K | Direct | Mar 28, 2025 (1d) |
| Mar 6, 2025 | RXRX | ↓ Sell | 40,000 | $6.47 | $259K | Direct | Mar 7, 2025 (1d) |
| Feb 6, 2025 | RXRX | ↓ Sell | 40,000 | $7.90 | $316K | Direct | Feb 7, 2025 (1d) |
| Jan 10, 2025 | RXRX | ↓ Sell | 40,000 | $7.18 | $287K | Direct | Jan 13, 2025 (3d) |
| Dec 5, 2024 | RXRX | ↓ Sell | 40,000 | $7.14 | $286K | Direct | Dec 6, 2024 (1d) |
| Nov 14, 2024 | RXRX | ↓ Sell | 40,000 | $7.54 | $302K | Direct | Nov 15, 2024 (1d) |
| Oct 3, 2024 | RXRX | ↓ Sell | 40,000 | $6.12 | $245K | Direct | Oct 4, 2024 (1d) |
| Sep 5, 2024 | RXRX | ↓ Sell | 40,000 | $6.09 | $244K | Direct | Sep 6, 2024 (1d) |
| Aug 8, 2024 | RXRX | ↓ Sell | 50,000 | $6.86 | $343K | Direct | Aug 9, 2024 (1d) |
| Jul 11, 2024 | RXRX | ↓ Sell | 100,000 | $7.47 | $748K | Direct | Jul 12, 2024 (1d) |
| Jun 6, 2024 | RXRX | ↓ Sell | 100,000 | $8.71 | $871K | Direct | Jun 7, 2024 (1d) |
| May 2, 2024 | RXRX | ↓ Sell | 100,000 | $8.10 | $810K | Direct | May 3, 2024 (1d) |
| Apr 4, 2024 | RXRX | ↓ Sell | 80,000 | $8.93 | $714K | Direct | Apr 5, 2024 (1d) |
| Apr 4, 2024 | RXRX | ↓ Sell | 25,000 | $9.02 | $226K | by LAHWRAN-3 LLC | Apr 5, 2024 (1d) |
| Apr 3, 2024 | RXRX | ↓ Sell | 25,000 | $8.84 | $221K | by Gibson Family Trust | Apr 5, 2024 (2d) |
| Mar 28, 2024 | RXRX | ↓ Sell | 40,000 | $10.10 | $404K | Direct | Apr 1, 2024 (4d) |
| Mar 28, 2024 | RXRX | ↓ Sell | 25,000 | $10.10 | $253K | by Gibson Family Trust | Apr 1, 2024 (4d) |
| Mar 6, 2024 | RXRX | ↓ Sell | 36,319 | $11.86 | $431K | Direct | Mar 8, 2024 (2d) |
| Mar 6, 2024 | RXRX | ↓ Sell | 20,000 | $11.55 | $231K | By LAHWRAN-4 LLC | Mar 8, 2024 (2d) |
| Mar 6, 2024 | RXRX | ↓ Sell | 4,000 | $11.56 | $46K | by LAHWRAN-3 LLC | Mar 8, 2024 (2d) |
| Mar 6, 2024 | RXRX | ↓ Sell | 1,000 | $11.56 | $12K | by Gibson Family Trust | Mar 8, 2024 (2d) |
| Feb 7, 2024 | RXRX | ↓ Sell | 48,272 | $9.22 | $445K | Direct | Feb 9, 2024 (2d) |
| Jan 3, 2024 | RXRX | ↓ Sell | 30,853 | $9.49 | $293K | Direct | Jan 5, 2024 (2d) |
| Jan 3, 2024 | RXRX | ↓ Sell | 20,000 | $9.51 | $190K | by LAHWRAN-4 LLC | Jan 5, 2024 (2d) |
| Jan 3, 2024 | RXRX | ↓ Sell | 4,000 | $9.51 | $38K | by LAHWRAN-3 LLC | Jan 5, 2024 (2d) |
| Jan 3, 2024 | RXRX | ↓ Sell | 1,000 | $9.49 | $9K | by Gibson Family Trust | Jan 5, 2024 (2d) |
| Dec 6, 2023 | RXRX | ↓ Sell | 59,829 | $7.49 | $448K | Direct | Dec 8, 2023 (2d) |
| Nov 1, 2023 | RXRX | ↓ Sell | 37,177 | $5.20 | $193K | Direct | Nov 3, 2023 (2d) |
| Nov 1, 2023 | RXRX | ↓ Sell | 20,000 | $5.11 | $102K | by LAHWRAN-4 LLC | Nov 3, 2023 (2d) |
| Nov 1, 2023 | RXRX | ↓ Sell | 4,000 | $5.14 | $21K | by LAHWRAN-3 LLC | Nov 3, 2023 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RXRX insiders
Open-market trades in the last 12 months
About Christopher Gibson's insider trades
Christopher Gibson is a director at Recursion Pharmaceuticals (RXRX). Since Dec 7, 2021, Christopher has reported no open-market purchases and 157 sales worth $39.1M on SEC Form 4. In the last 12 months: 11 sales ($1.7M).
Their filings also include conversions (76 filings), option exercises (37 filings), gifts (31 filings), shares withheld for taxes (22 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RXRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.